LC24 Studio: Rapid tumour classification and the potential to transform patient care
Simon Payne, a consultant neuropathologist from Nottingham University Hospitals NHS Trust, Matt Loose, a researcher from Nottingham, and Gordon Sanghera, CEO, of Oxford Nanopore Technologies join Zoe on the sofa for this session. Together, they discussed a groundbreaking project that leverages nanopore technology for rapid tumour classification, significantly advancing the field of neuropathology and transforming patient care.
Summary
Role of Neuropathologists and Genomics: Simon explains that neuropathologists analyse nervous system samples, focusing on living patients rather than the deceased. Genomics has revolutionized their work by providing molecular insights into tumours, allowing for more accurate diagnoses and predictions.
Nanopore technology and its Impact: The project, in collaboration with Matt, uses nanopore sequencing to rapidly classify tumours within hours, significantly reducing the waiting time for diagnosis from several weeks. This quick turnaround is crucial for guiding surgeries and improving patient outcomes.
Funding and Implementation Challenges: Matt discusses the complexities of securing funding and the logistical challenges of integrating research into clinical practice. The project aims to transform the speed and accuracy of cancer diagnoses, impacting patients and the healthcare system positively.
Future Plans and Network Expansion: The team plans to expand their research through events and collaborations, aiming to share their findings and methodologies globally. The vision includes standardizing rapid tumour classification to benefit patients worldwide, starting with a dedicated event in Nottingham and further international cooperation.